Abstract: Colorectal cancer is the third most common cancer and the second cause of cancer-related deaths. Rectal cancer presents roughly one-third of all colorectal cancer cases and differs from it on both anatomical and molecular levels. While standard treatment of colon cancer patients is radical surgery, rectal cancer is usually treated with pre-operative chemoradiotherapy followed by total mesorectal excision, which requires precise estimation of TNM staging. Unfortunately, stage evaluation is based solely on imaging modalities, and they often do not correlate with postoperative pathological findings. Moreover, approximately half of rectal cancer patients do not respond to such pre-operative therapy, so they are exposed to its toxic effects without any clinical benefit. Thus, biomarkers that could precisely predict pre-operative TNM staging, and especially response to therapy, would significantly advance rectal cancer treatment-but till now, no such biomarker has been identified. In cancer research, microRNAs are emerging biomarkers due to their connection with carcinogenesis and exceptional stability. Circulating miRNAs are promising non-invasive biomarkers that could allow monitoring of a patient throughout the whole therapeutic process. This mini-review aims to summarize the current knowledge on miRNAs and circulating miRNAs involved in the prediction of response to treatment and pre-operative staging in rectal cancer patients.

Department of Molecular Medicine European Institute of Technology 625 00 Brno Czech Republic

Department of Surgery University Hospital Brno 625 00 Brno Czech Republic

Zobrazit více v PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Christensen T.D., Jensen S.G., Larsen F.O., Nielsen D.L. Systematic review: Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer. J. Bone Oncol. 2018;13:97–105. doi: 10.1016/j.jbo.2018.09.009. PubMed DOI PMC

Frambach P., Pucciarelli S., Perin A., Zuin M., Toppan P., Maretto I., Urso E.D.L., Spolverato G. Metastatic pattern and new primary tumours after neoadjuvant therapy and surgery in rectal cancer. Colorectal Dis. 2018;20:O326–O334. doi: 10.1111/codi.14427. PubMed DOI

Edge S.B., Compton C.C. The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann. Surg. Oncol. 2010;17:1471–1474. doi: 10.1245/s10434-010-0985-4. PubMed DOI

Tawadros P.S., Paquette I.M., Hanly A.M., Mellgren A.F., Rothenberger D.A., Madoff R.D. Adenocarcinoma of the Rectum in Patients Under Age 40 Is Increasing: Impact of Signet-Ring Cell Histology. Dis. Colon. Rectum. 2015;58:474–478. doi: 10.1097/DCR.0000000000000318. PubMed DOI

Grass F., Mathis K. Novelties in treatment of locally advanced rectal cancer. F1000 Res. 2018;7:1868. doi: 10.12688/f1000research.16194.1. PubMed DOI PMC

Bernier L., Balyasnikova S., Tait D., Brown G. Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer. Curr. Colorectal. Cancer Rep. 2018;14:37–55. doi: 10.1007/s11888-018-0398-5. PubMed DOI PMC

Smith J.J., Strombom P., Chow O.S., Roxburgh C.S., Lynn P., Eaton A., Widmar M., Ganesh K., Yaeger R., Cercek A. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol. 2019;5:e185896. doi: 10.1001/jamaoncol.2018.5896. PubMed DOI PMC

Kim S.H., Chang H.J., Kim D.Y., Park J.W., Baek J.Y., Kim S.Y., Park S.C., Oh J.H., Yu A., Nam B.H. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? Cancer Res. Treat. 2016;48:998–1009. doi: 10.4143/crt.2015.254. PubMed DOI PMC

Du B., Wang X., Wu D., Wang T., Yang X., Wang J., Shi X., Chen L., Zhang W. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer. Mol. Med. Rep. 2018;18:1909–1916. doi: 10.3892/mmr.2018.9215. PubMed DOI PMC

Slattery M.L., Herrick J.S., Mullany L.E., Samowitz W.S., Sevens J.R., Sakoda L., Wolff R.K. The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer. Genes Chromosomes Cancer. 2017;56:769–787. doi: 10.1002/gcc.22481. PubMed DOI PMC

Greystoke A., Ayub M., Rothwell D.G., Morris D., Burt D., Hodgkinson C.L., Morrow C.J., Smith N., Aung K., Valle J., et al. Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Mol. Oncol. 2016;10:282–291. doi: 10.1016/j.molonc.2015.10.004. PubMed DOI PMC

Ishikawa H., Yamada H., Taromaru N., Kondo K., Nagura A., Yamazaki M., Ando Y., Munetsuna E., Suzuki K., Ohashi K., et al. Stability of serum high-density lipoprotein-microRNAs for preanalytical conditions. Ann. Clin. Biochem. 2017;54:134–142. doi: 10.1177/0004563216647086. PubMed DOI

MacFarlane L.A.R., Murphy P. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genomics. 2010;11:537–561. doi: 10.2174/138920210793175895. PubMed DOI PMC

Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014;15:509–524. doi: 10.1038/nrm3838. PubMed DOI

Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009;11:228–234. doi: 10.1038/ncb0309-228. PubMed DOI

Huntley R.P., Sitnikov D., Orlic-Milacic M., Balakrishnan R., D’Eustachio P., Gillespie M.E., Howe D., Kalea A.Z., Maegdefessel L., Osumi-Sutherland D., et al. Guidelines for the functional annotation of microRNAs using the Gene Ontology. RNA. 2016;22:667–676. doi: 10.1261/rna.055301.115. PubMed DOI PMC

Kozomara A., Griffiths-Jones S. Mirbase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68–D73. doi: 10.1093/nar/gkt1181. PubMed DOI PMC

Sohel M.H. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achiev. Life Sci. 2016;10:175–186. doi: 10.1016/j.als.2016.11.007. DOI

Eslamizadeh S., Heidari M., Agah S., Faghihloo E., Ghazi H., Mirzaei A., Akbari A. The Role of MicroRNA Signature as Diagnostic Biomarkers in Different Clinical Stages of Colorectal Cancer. Cell J. Yakhteh. 2018;20:220–230. doi: 10.22074/cellj.2018.5366. PubMed DOI PMC

Tang S., Wu W.K., Li X., Wong S.H., Wong N., Chan M.T., Sung J.J., Yu J. Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Sci. Rep. 2016;15:24466. doi: 10.1038/srep24466. PubMed DOI PMC

Weber D., Amar L., Gödde D., Prinz C. Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. Oncotarget. 2018;9:27256–27267. doi: 10.18632/oncotarget.25535. PubMed DOI PMC

Bullock M.D., Pickard K.M., Nielsen B.S., Sayan A.E., Jenei V., Mellone M., Mitter R., Primrose J.N., Thomas G.J., Packham G.K., et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis. 2013;4:e684. doi: 10.1038/cddis.2013.213. PubMed DOI PMC

Wu W. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol. Rep. 2012;37:662–668. doi: 10.3892/or.2012.1769. PubMed DOI

Gaedcke J., Grade M., Camps J., Sokilde R., Kaczkowski B., Schetter A.J., Difilippantonio M.J., Harris C.C., Ghadimi B.M., Møller S., et al. The Rectal Cancer microRNAome-microRNA Expression in Rectal Cancer and Matched Normal Mucosa. Clin. Cancer Res. 2012;18:4919–4930. doi: 10.1158/1078-0432.CCR-12-0016. PubMed DOI PMC

Mu J.F., Wang X.D., Sun P.D. Expression of miR-31 in rectal cancer patients and its effect on proliferation ability of rectal cancer cells SW837. Eur. Rev. Med. Pharmacol. Sci. 2018;22:8675–8681. doi: 10.26355/eurrev_201812_16632. PubMed DOI

Igarashi H., Kurihara H., Mitsuhashi K., Ito M., Okuda H., Kanno S., Naito T., Yoshii S., Takahashi H., Kusumi T., et al. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Ann. Surg. Oncol. 2015;22:2640–2648. doi: 10.1245/s10434-014-4264-7. PubMed DOI

Mosakhani N., Lahti L., Borze I., Karjalainen-Lindsberg M.L., Sundström J., Ristamäki R., Osterlund P., Knuutila S., Sarhadi V.K. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet. 2012;205:545–551. doi: 10.1016/j.cancergen.2012.08.003. PubMed DOI

Manceau G., Imbeaud S., Thiebaut R., Liebaert F., Fontaine K., Rousseau F., Génin B., Le Corre D., Didelot A., Vincent M., et al. Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. Clin. Cancer Res. 2014;20:3338–3347. doi: 10.1158/1078-0432.CCR-13-2750. PubMed DOI

Laurent-Puig P., Grisoni M.L., Heinemann V., Liebaert F., Neureiter D., Jung A., Montestruc F., Gaston-Mathe Y., Thiébaut R., Stintzing S. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. Clin. Cancer Res. 2019;25:134–141. doi: 10.1158/1078-0432.CCR-18-1324. PubMed DOI

Mlcochova J., Faltejskova-Vychytilova P., Ferracin M., Zagatti B., Radova L., Svoboda M., Nemecek R., John S., Kiss I., Vyzula R., et al. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. 2015;6:38695–38704. doi: 10.18632/oncotarget.5735. PubMed DOI PMC

Yang Y., Tang T., Peng W., Xia L., Wang X., Duan B., Shu Y. The comparison of miR-155 with computed tomography and computed tomography plus serum amyloid A protein in staging rectal cancer. J. Surg. Res. 2015;193:764–771. doi: 10.1016/j.jss.2014.08.040. PubMed DOI

Li Y., Wang J., Ma X.W., Tan L., Yan Y.L., Xue C.F., Hui B.N., Liu R., Ma H.L., Ren J. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int. J. Biol. Sci. 2016;12:1022–1031. doi: 10.7150/ijbs.15438. PubMed DOI PMC

Heo S.H. Multimodal imaging evaluation in staging of rectal cancer. World J. Gastroenterol. 2014;20:4244. doi: 10.3748/wjg.v20.i15.4244. PubMed DOI PMC

Balyasnikova S., Brown G. Optimal Imaging Strategies for Rectal Cancer Staging and Ongoing Management. Curr. Treat. Options Oncol. 2016;17:32. doi: 10.1007/s11864-016-0403-7. PubMed DOI PMC

Jhaveri K.S., Hosseini-Nik H. MRI of Rectal Cancer: An Overview and Update on Recent Advances. Am. J. Roentgenol. 2015;205:W42–W55. doi: 10.2214/AJR.14.14201. PubMed DOI

Hotchi M. MicroRNA expression is able to predict response to chemoradiotherapy in rectal cancer. Mol. Clin. Oncol. 2012;1:137–142. doi: 10.3892/mco.2012.9. PubMed DOI PMC

Svoboda M., Sana J., Fabian P., Kocakova I., Gombosova J., Nekvindova J., Radova L., Vyzula R., Slaby O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat. Oncol. 2012;7:195. doi: 10.1186/1748-717X-7-195. PubMed DOI PMC

Kheirelseid E.A.H., Miller N., Chang K.H., Curran C., Hennessey E., Sheehan M., Newell J., Lemetre C., Balls G., Kerin M.J. MiRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int. J. Colorectal. Dis. 2013;28:247–260. doi: 10.1007/s00384-012-1549-9. PubMed DOI

Lopes-Ramos C.M., Habr-Gama A., Quevedo B.d.S., Felício N.M., Bettoni F., Koyama F.C., Asprino P.F., Galante P.A., Gama-Rodrigues J., Camargo A.A., et al. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med. Genomics. 2014;7:68. doi: 10.1186/s12920-014-0068-7. PubMed DOI PMC

Caramés C., Cristobal I., Moreno V., Marín J., González-Alonso P., Torrejón B., Minguez P., Leon A., Martín J.I., Hernández R., et al. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int. J. Mol. Sci. 2016;17:878. doi: 10.3390/ijms17060878. PubMed DOI PMC

Salvi S., Molinari C., Foca F., Teodorani N., Saragoni L., Puccetti M., Passardi A., Tamberi S., Avanzolini A., Lucci E., et al. MiR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. OncoTargets Ther. 2016;9:2735–2742. doi: 10.2147/OTT.S105760. PubMed DOI PMC

Millino C., Maretto I., Pacchioni B., Digito M., De Paoli A., Canzonieri V., D’Angelo E., Agostini M., Rizzolio F., Giordano A., et al. Gene and MicroRNA Expression Are Predictive of Tumor Response in Rectal Adenocarcinoma Patients Treated with Preoperative Chemoradiotherapy: COMBINED miRNAS AND GENE EXPRESSION. J. Cell Physiol. 2017;232:426–435. doi: 10.1002/jcp.25441. PubMed DOI

Eriksen A.H.M., Sørensen F.B., Andersen R.F., Jakobsen A., Hansen T.F. Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. Oncol. Lett. 2017;14:201–209. doi: 10.3892/ol.2017.6141. PubMed DOI PMC

D’Angelo E., Zanon C., Sensi F., Digito M., Rugge M., Fassan M., Scarpa M., Pucciarelli S., Nitti D., Agostini M. MiR-194 as predictive biomarker of responsiveness to neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. J. Clin. Pathol. 2018;71:344–350. doi: 10.1136/jclinpath-2017-204690. PubMed DOI

Campayo M., Navarro A., Benítez J.C., Santasusagna S., Ferrer C., Monzó M., Cirera L. MiR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. PLoS ONE. 2018;13:e0206542. doi: 10.1371/journal.pone.0206542. PubMed DOI PMC

Luo J., Liu L., Zhou N., Shen J., Sun Q., Zhu Y. miR-519b-3p promotes responsiveness to preoperative chemoradiotherapy in rectal cancer patients by targeting ARID4B. Gene. 2018;655:84–90. doi: 10.1016/j.gene.2018.02.056. PubMed DOI

Pettit C., Webb A., Walston S., Chatterjee M., Chen W., Frankel W., Croce C., Williams T.M. MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma. Oncotarget. 2018;9:28951–28964. doi: 10.18632/oncotarget.25652. PubMed DOI PMC

Orosz E., Kiss I., GyöNgyi Z., Varjas T. Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer. In Vivo. 2018;32:1333–1337. doi: 10.21873/invivo.11383. PubMed DOI PMC

Meltzer S., Bjørnetrø T., Lyckander L.G., Flatmark K., Dueland S., Samiappan R., Johansen C., Kalanxhi E., Ree A.H., Redalen K.R. Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Transl. Oncol. 2019;12:1038–1044. doi: 10.1016/j.tranon.2019.04.014. PubMed DOI PMC

Mjelle R., Sellæg K., Sætrom P., Thommesen L., Sjursen W., Hofsli E. Identification of metastasis-associated microRNAs in serum from rectal cancer patients. Oncotarget. 2017;8:90077–90089. doi: 10.18632/oncotarget.21412. PubMed DOI PMC

Azizian A., Kramer F., Jo P., Wolff H.A., Beißbarth T., Skarupke R., Bernhardt M., Grade M., Ghadimi B.M., Gaedcke J. Preoperative Prediction of Lymph Node Status by Circulating Mir-18b and Mir-20a During Chemoradiotherapy in Patients with Rectal Cancer. World J. Surg. 2015;39:2329–2335. doi: 10.1007/s00268-015-3083-8. PubMed DOI

D’Angelo E., Fassan M., Maretto I., Pucciarelli S., Zanon C., Digito M., Rugge M., Nitti D., Agostini M. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget. 2016;7:28647–28657. doi: 10.18632/oncotarget.8725. PubMed DOI PMC

Yu J., Li N., Wang X., Ren H., Wang W., Wang S., Rugge M., Nitti D., Agostini M. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget. 2016;7:64233–64243. doi: 10.18632/oncotarget.11649. PubMed DOI PMC

Hiyoshi Y., Akiyoshi T., Inoue R., Murofushi K., Yamamoto N., Fukunaga Y., Ueno M., Baba H., Mori S., Yamaguchi T. Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Oncotarget. 2017;8:79201–79211. doi: 10.18632/oncotarget.16760. PubMed DOI PMC

Bjørnetrø T., Redalen K.R., Meltzer S., Thusyanthan N.S., Samiappan R., Jegerschöld C., Handeland K.R., Ree A.H. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J. Extracell. Vesicles. 2019;8:1567219. doi: 10.1080/20013078.2019.1567219. PubMed DOI PMC

Sun W., Li G., Wan J., Zhu J., Shen W., Zhang Z. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;7:69507–69517. doi: 10.18632/oncotarget.10875. PubMed DOI PMC

Troncarelli Flores B.C., Souza e Silva V., Ali Abdallah E., Mello C.A.L., Gobo Silva M.L., Gomes Mendes G., Camila Braun A., Aguiar Junior S., Thomé Domingos Chinen L. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients. Cells. 2019;8:641. doi: 10.3390/cells8070641. PubMed DOI PMC

Sclafani F., Chau I., Cunningham D., Hahne J.C., Vlachogiannis G., Eltahir Z., Lampis A., Braconi C., Kalaitzaki E., De Castro D.G., et al. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Sci. Rep. 2018;8:1445. doi: 10.1038/s41598-018-19212-5. PubMed DOI PMC

Glinge C., Clauss S., Boddum K., Jabbari R., Jabbari J., Risgaard B., Tomsits P., Hildebrand B., Kääb S., Wakili R., et al. Stability of Circulating Blood-Based MicroRNAs–Pre-Analytic Methodological Considerations. PLoS ONE. 2017;12:e0167969. doi: 10.1371/journal.pone.0167969. PubMed DOI PMC

Poel D., Buffart T.E., Oosterling-Jansen J., Verheul H.M., Voortman J. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Exp. Mol. Med. 2018;50:e454. doi: 10.1038/emm.2017.288. PubMed DOI PMC

Lo Nigro C., Ricci V., Vivenza D., Granetto C., Fabozzi T., Miraglio E., Merlano M.C. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J. Gastroenterol. 2016;22:6944. doi: 10.3748/wjg.v22.i30.6944. PubMed DOI PMC

Rapisuwon S., Vietsch E.E., Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput. Struct. Biotechnol. J. 2016;14:211–222. doi: 10.1016/j.csbj.2016.05.004. PubMed DOI PMC